DE69620222D1 - Arylethanolaminderivate und deren verwendung als agonisten von atypischen beta-adrenorezeptoren - Google Patents

Arylethanolaminderivate und deren verwendung als agonisten von atypischen beta-adrenorezeptoren

Info

Publication number
DE69620222D1
DE69620222D1 DE69620222T DE69620222T DE69620222D1 DE 69620222 D1 DE69620222 D1 DE 69620222D1 DE 69620222 T DE69620222 T DE 69620222T DE 69620222 T DE69620222 T DE 69620222T DE 69620222 D1 DE69620222 D1 DE 69620222D1
Authority
DE
Germany
Prior art keywords
alkyl
pct
trifluoromethyl
alkoxy
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69620222T
Other languages
English (en)
Other versions
DE69620222T2 (de
Inventor
Richard Howard Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE69620222D1 publication Critical patent/DE69620222D1/de
Publication of DE69620222T2 publication Critical patent/DE69620222T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69620222T 1995-12-08 1996-12-06 Arylethanolaminderivate und deren verwendung als agonisten von atypischen beta-adrenorezeptoren Expired - Fee Related DE69620222T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9525177.3A GB9525177D0 (en) 1995-12-08 1995-12-08 Chemical compounds
PCT/EP1996/005469 WO1997021665A1 (en) 1995-12-08 1996-12-06 Arylethanolamine derivatives and their use as agonists of atypical beta-adrenoceptors

Publications (2)

Publication Number Publication Date
DE69620222D1 true DE69620222D1 (de) 2002-05-02
DE69620222T2 DE69620222T2 (de) 2002-10-24

Family

ID=10785166

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620222T Expired - Fee Related DE69620222T2 (de) 1995-12-08 1996-12-06 Arylethanolaminderivate und deren verwendung als agonisten von atypischen beta-adrenorezeptoren

Country Status (9)

Country Link
US (1) US6048872A (de)
EP (1) EP0865421B1 (de)
JP (1) JP2000506498A (de)
AT (1) ATE215064T1 (de)
AU (1) AU1191597A (de)
DE (1) DE69620222T2 (de)
ES (1) ES2175166T3 (de)
GB (1) GB9525177D0 (de)
WO (1) WO1997021665A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102407D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Process
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
US7034053B2 (en) 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052127A1 (de) 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154761A (en) * 1976-02-09 1979-05-15 Allen & Hanburys Limited Pharmacologically active compounds
GB1593651A (en) * 1977-02-03 1981-07-22 Allen & Hanburys Ltd Amides
DE3428526A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue aminoalkohole, verfahren zu deren herstellung sowie diese verbindung enthaltende arzneimittel
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
WO1995033724A1 (en) * 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists

Also Published As

Publication number Publication date
ATE215064T1 (de) 2002-04-15
AU1191597A (en) 1997-07-03
WO1997021665A1 (en) 1997-06-19
US6048872A (en) 2000-04-11
EP0865421B1 (de) 2002-03-27
DE69620222T2 (de) 2002-10-24
ES2175166T3 (es) 2002-11-16
GB9525177D0 (en) 1996-02-07
JP2000506498A (ja) 2000-05-30
EP0865421A1 (de) 1998-09-23

Similar Documents

Publication Publication Date Title
DK0687268T3 (da) Spiroazacykliske derivater som substans P-antagonister
BR9610960A (pt) Derivados de 8-azabiciclo [3.2.1] oct -2- eno sua preparação e uso
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
ATE149497T1 (de) Azanorbornanderivate
DK0660823T3 (da) N-cyano-N-pyridylguanidiner som serotoninantagonister
AR013078A1 (es) Derivados de tetrahidroisoquinoleina, una sal de los mismos, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de losmismos en la preparacion de un medicamento.
SE9502921D0 (sv) New compounds
DE69620222D1 (de) Arylethanolaminderivate und deren verwendung als agonisten von atypischen beta-adrenorezeptoren
FI973221A (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
NO954692L (no) Substituerte beta-aryl og beta-heteroaryl-alfa-cyanoakrylamid-derivater som tyrosinkinase inhibitorer
ATE198316T1 (de) N-bis- oder n-tris-((1,2-dicarboxy-ethoxy)-ethyl)-amin-deri ate und herstellung und anwendung derselben
ATE234818T1 (de) Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69102762D1 (de) Beta-phenylisoserinderivate, ihre herstellung und ihre anwendung.
ES2181772T3 (es) Compuesto de eter, su utilizacion e intermediario para la obtencion de este compuesto.
NO970435D0 (no) Nye, 3-substituerte 3H-2,3-benzodiazepinderivater, fremstilling av dem og anvendelse av dem som legemidler
ATE191465T1 (de) Carbamoylcarbonsäureamide
ATE203533T1 (de) INDOLDERIVATE ALS PRODRUGS VON ß5-HT1-LIKEß REZEPTOR AGONISTEN
FI961793A0 (fi) Muistia parantavina aineina käyttökelpoiset 3-aryyli-4-alkyyli- ja 4,5-dialkyyli 4H-1,2,4-triatsolit
HUP0002132A2 (hu) Új arilpiperazinilalkil-3(2H)-piridazinon-vegyületek, eljárás előállításukra és hatóanyagként ilyen vegyületeket tartalmazó készítmények
IT1286141B1 (it) Derivati diammidici dell'acido antranilico ad attivita' antigastrinica procedimento per la loro preparazione e loro uso farmaceutico.
FI955141A (fi) Pyrido(1,2,3-de)kinoksaliinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeissä
TH30603A (th) สารประกอบแบบใหม่
DE69612413D1 (de) 1-(Hetero)Arylvinyl-5H-2,3-benzodiazepinderivative verwendbar zur Behandlung von Erkrankungen des Zentralnervensystems, sowie Benzopyrylium Intermediate zu ihrer Herstellung

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee